Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 2 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
1(100.0%)
1Total
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (2)

Showing 2 of 2 trials
NCT07070193Not Yet Recruiting

Longitudinal Cohort Study on Immune Thrombocytopenia Complicated With Acute Ischemic Stroke

Role: collaborator

NCT04516993Phase 2Completed

CHinese Acute Tissue-Based Imaging Selection for Lysis In Stroke -Tenecteplase II

Role: collaborator

All 2 trials loaded